Integra LifeSciences Holdings Corporation $IART Shares Bought by Glenmede Trust Co. NA

Glenmede Trust Co. NA boosted its holdings in shares of Integra LifeSciences Holdings Corporation (NASDAQ:IART) by 27.4% in the first quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 984,686 shares of the life sciences company’s stock after buying an additional 211,774 shares during the quarter. Glenmede Trust Co. NA’s holdings in Integra LifeSciences were worth $9,276,000 at the end of the most recent reporting period.

Other large investors have also made changes to their positions in the company. Osaic Holdings Inc. increased its stake in shares of Integra LifeSciences by 36.6% in the second quarter. Osaic Holdings Inc. now owns 4,119 shares of the life sciences company’s stock worth $51,000 after acquiring an additional 1,104 shares during the period. State of Tennessee Department of Treasury boosted its holdings in Integra LifeSciences by 7.9% in the fourth quarter. State of Tennessee Department of Treasury now owns 26,745 shares of the life sciences company’s stock valued at $332,000 after purchasing an additional 1,964 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its position in Integra LifeSciences by 5.1% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 40,441 shares of the life sciences company’s stock worth $889,000 after purchasing an additional 1,975 shares during the period. Capital Fund Management S.A. grew its position in Integra LifeSciences by 5.7% during the 3rd quarter. Capital Fund Management S.A. now owns 37,322 shares of the life sciences company’s stock worth $535,000 after purchasing an additional 1,997 shares during the period. Finally, Global Retirement Partners LLC purchased a new position in shares of Integra LifeSciences during the 4th quarter valued at about $25,000. 84.78% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

IART has been the topic of a number of recent research reports. Weiss Ratings downgraded Integra LifeSciences from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Thursday. BMO Capital Markets started coverage on Integra LifeSciences in a report on Wednesday, July 8th. They issued a “market perform” rating and a $19.00 price target for the company. Wall Street Zen cut shares of Integra LifeSciences from a “strong-buy” rating to a “buy” rating in a research note on Saturday, July 18th. Citigroup reaffirmed a “neutral” rating and set a $19.00 target price (up from $16.00) on shares of Integra LifeSciences in a report on Wednesday, July 8th. Finally, Truist Financial boosted their target price on shares of Integra LifeSciences from $14.00 to $19.00 and gave the company a “hold” rating in a research note on Thursday, July 16th. One analyst has rated the stock with a Buy rating, five have given a Hold rating and two have given a Sell rating to the company’s stock. According to MarketBeat.com, the company currently has an average rating of “Reduce” and a consensus price target of $18.86.

Integra LifeSciences Price Performance

Shares of Integra LifeSciences stock opened at $17.88 on Tuesday. The firm has a market cap of $1.39 billion, a PE ratio of -198.64, a P/E/G ratio of 1.40 and a beta of 1.21. Integra LifeSciences Holdings Corporation has a twelve month low of $8.70 and a twelve month high of $20.49. The company has a quick ratio of 2.11, a current ratio of 3.60 and a debt-to-equity ratio of 1.75. The business has a 50-day moving average price of $17.75 and a 200 day moving average price of $13.51.

Integra LifeSciences (NASDAQ:IART) last issued its quarterly earnings results on Wednesday, July 29th. The life sciences company reported $0.56 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.48 by $0.08. Integra LifeSciences had a positive return on equity of 18.30% and a negative net margin of 0.44%.The company had revenue of $418.76 million for the quarter, compared to the consensus estimate of $417.54 million. Integra LifeSciences has set its Q3 2026 guidance at 0.530-0.610 EPS and its FY 2026 guidance at 2.400-2.500 EPS. Sell-side analysts predict that Integra LifeSciences Holdings Corporation will post 2.46 earnings per share for the current fiscal year.

Integra LifeSciences Company Profile

Integra LifeSciences Corporation is a global medical technology company specializing in products and innovations for neurosurgery, regenerative medicine and reconstructive procedures. The company develops and markets surgical instruments, implants and advanced wound care solutions designed to support tissue repair and functional recovery. Its product portfolio includes collagen-based matrices, dural substitutes, hemostatic agents and specialized spinal and peripheral fixation devices.

Founded in 1989 and headquartered in Plainsboro, New Jersey, Integra has expanded its capabilities through targeted acquisitions and internal research efforts.